By In a recent move that has caught the attention of investors, R. Michael Carruthers, the Chief Financial Officer of Edgewise Therapeutics, Inc. (NASDAQ:EWTX), has sold a significant portion of his company stock. According to the latest filings, Carruthers sold shares worth over $3.5 million.
The transactions, which took place on September 20th, involved the sale of 75,092 shares of Edgewise Therapeutics’ common stock at prices ranging from $28.5477 to $28.5862, resulting in a total sale value of approximately $3,573,979. Additionally, Carruthers acquired 96,068 shares through option exercises at a fixed price of $1.93, totaling $185,411.
These sales and purchases are part of the executive’s stock trading plan and provide insight into the financial moves of Edgewise Therapeutics’ upper management. Following these transactions, Carruthers’ direct ownership in the company has been adjusted to 6,904 shares of common stock.
It’s worth noting that the prices at which the stock was sold represent an average, as the shares were sold in multiple transactions with varying prices within the reported range. This is a common practice to provide a general idea of the transaction values without disclosing each specific trade.
For investors following insider activity as a signal for their trading strategies, such moves can be of interest as they reflect the actions of those with in-depth knowledge of the company. Edgewise Therapeutics, based in Boulder, Colorado, specializes in pharmaceutical preparations and has been a player in the life sciences sector.
Investors and security holders of Edgewise Therapeutics can request detailed information about the exact number of shares sold at each price point within the range, as stated by the reporting officer in the footnotes of the filing.
The recent stock sales by the CFO of Edgewise Therapeutics are part of the ongoing financial disclosures required by executives and are publicly available for review by investors and regulatory bodies.
In other recent news, Edgewise Therapeutics has seen a flurry of activity from prominent analyst firms. RBC Capital Markets raised its price target for Edgewise from $32.00 to $42.00, maintaining an Outperform rating, following the release of promising data for the company’s ‘7500 drug candidate. Truist Securities also increased its price target for the company from $25.00 to $33.00, keeping a Buy rating, based on the potential of Edgewise’s Hypertrophic Cardiomyopathy (HCM) program.
Edgewise reported positive results from Phase 1 and Phase 2 trials of its heart disease drug, EDG-7500, with a new 28-day trial initiated and initial data expected in the first quarter of 2025. In addition, the company approved the 2024 Inducement Equity Incentive Plan, reserving 2 million shares of common stock for new equity awards.
Piper Sandler maintained its Overweight rating on Edgewise, citing upcoming milestones such as the Phase 1 trials for EDG-7500. Furthermore, the company is preparing for data readouts from its sevasemten programs in Phase 2 trials by the end of 2024. These recent developments highlight Edgewise’s commitment to advancing its pipeline of innovative therapeutics.
InvestingPro Insights
In the context of the recent stock sales by R. Michael Carruthers, CFO of Edgewise Therapeutics, Inc. (NASDAQ:EWTX), investors might be interested in various financial metrics and recent performance data that could shed light on the company’s current financial health and market sentiment. According to InvestingPro data, Edgewise Therapeutics holds a market capitalization of approximately $2.43 billion. Despite challenging market conditions, the company has demonstrated a significant return over the last week, with a 35.92% increase in price total return.
InvestingPro Tips suggest that Edgewise Therapeutics holds more cash than debt on its balance sheet, which is a positive sign for financial stability. Additionally, the company’s liquid assets exceed its short-term obligations, indicating a solid liquidity position. These factors might provide some investors with confidence in the company’s ability to manage its finances despite an analyst consensus that the company may not be profitable this year.
With a strong return over the last month, three months, and six months, investors may find the stock’s recent performance encouraging. The price has seen a large uptick, with a 62.0% total return over the last six months and a 337.84% return over the last year. It’s also notable that the company’s shares are trading at 86.4% of their 52-week high, as of the previous close.
For those interested in further analysis and additional InvestingPro Tips, there are 10 more tips listed in the InvestingPro product, which can be accessed for Edgewise Therapeutics at https://www.investing.com/pro/EWTX. This information could be valuable for investors looking to make informed decisions based on the latest data and expert insights.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
